PURCHASE, N.Y., Aug 17, 2005 (BUSINESS WIRE) -- The Food and Drug Administration (FDA) has requested a two week extension for the review of Nutrition 21, Inc.'s (NXXI) qualified health claim petition associating chromium picolinate with a reduced risk of insulin resistance, type 2 diabetes and related diseases. The company has agreed to the extension.
About Nutrition 21
Nutrition 21 is a nutritional bioscience company and the maker of chromium-based supplements with health benefits substantiated by clinical research. The company markets Chromax chromium picolinate, which is the most-studied form of the essential mineral chromium. Nutrition 21 holds 36 patents for nutrition products and uses, 27 of which are for chromium compounds and their uses. More information is available at www.nutrition21.com.